• 1. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 2. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 3. Excess electrons in lithium–ethylamine solutions—density, electrical conductivity and EPR studies
  Phys. Chem. Chem. Phys., 1999,1, 3561-3565
• 4. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207
• 5. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imaging
  Ghazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683

Research Brief on 3-Amino Ropivacaine (CAS: 247061-08-1): Recent Advances and Applications

3-Amino Ropivacaine (CAS: 247061-08-1) is a derivative of the widely used local anesthetic ropivacaine, which has garnered significant attention in recent years due to its potential pharmacological advantages. This research brief synthesizes the latest findings on 3-Amino Ropivacaine, focusing on its chemical properties, mechanism of action, and emerging applications in clinical and preclinical settings. The compound's unique structural modifications, including the introduction of an amino group, have been shown to influence its pharmacokinetics and pharmacodynamics, offering potential benefits such as reduced toxicity and prolonged duration of action.

Recent studies have explored the synthesis and optimization of 3-Amino Ropivacaine, with particular emphasis on improving its yield and purity. Advanced analytical techniques, such as high-performance liquid chromatography (HPLC) and nuclear magnetic resonance (NMR) spectroscopy, have been employed to characterize the compound and ensure its compliance with pharmaceutical standards. Additionally, in vitro and in vivo studies have demonstrated its efficacy in blocking sodium channels, a key mechanism underlying its anesthetic properties. These findings suggest that 3-Amino Ropivacaine could serve as a safer and more effective alternative to traditional local anesthetics.

One of the most promising aspects of 3-Amino Ropivacaine is its potential application in pain management, particularly in postoperative and chronic pain scenarios. Preclinical trials have indicated that the compound exhibits a favorable safety profile, with minimal cardiotoxicity and neurotoxicity compared to its parent molecule, ropivacaine. Furthermore, its enhanced selectivity for sensory neurons over motor neurons may reduce undesirable side effects, such as muscle weakness, commonly associated with local anesthetics. These attributes position 3-Amino Ropivacaine as a candidate for further clinical development.

In addition to its anesthetic properties, recent research has investigated the anti-inflammatory and antimicrobial effects of 3-Amino Ropivacaine. Preliminary data suggest that the compound may modulate inflammatory cytokines and exhibit bacteriostatic activity, which could expand its utility beyond pain management. For instance, its incorporation into wound dressings or implantable devices could potentially reduce infection rates and improve patient outcomes. However, further studies are needed to validate these findings and elucidate the underlying mechanisms.

Despite its promising potential, challenges remain in the development and commercialization of 3-Amino Ropivacaine. Regulatory hurdles, scalability of synthesis, and the need for extensive clinical trials are critical considerations. Nevertheless, the growing body of research underscores the compound's versatility and its potential to address unmet needs in anesthesia and analgesia. Future directions may include exploring its use in combination therapies, optimizing delivery systems, and investigating its effects in diverse patient populations.

In conclusion, 3-Amino Ropivacaine (CAS: 247061-08-1) represents a significant advancement in the field of local anesthetics, with its unique pharmacological profile and broad therapeutic potential. Ongoing research and development efforts are expected to further elucidate its benefits and pave the way for its clinical adoption. This brief highlights the importance of continued investment in innovative compounds like 3-Amino Ropivacaine to enhance patient care and improve outcomes in pain management and beyond.

• 2180-92-9(Bupivacaine)
• 22801-44-1(Mepivacaine)
• 24358-84-7((S)-Mepavacaine)
• 27262-43-7(N-Despropyl (R)-Ropivacaine)
• 27262-45-9((R)-Bupivacaine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)